Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + venetoclax + decitabine + azacitidine
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This drug refers to a combination therapy regimen consisting of the PD-1 inhibitor **tislelizumab**, the BCL-2 inhibitor **venetoclax**, and a hypomethylating agent (HMA) which can be either **decitabine** or **azacitidine**. Tislelizumab is a humanized IgG4 monoclonal antibody that targets the PD-1 receptor to restore anti-tumor T-cell activity. Venetoclax is an oral small molecule that selectively inhibits BCL-2, a pro-survival protein often overexpressed in hematologic malignancies, thereby promoting apoptosis. The hypomethylating agents decitabine and azacitidine work by reversing aberrant DNA methylation patterns and downregulating pro-survival proteins like MCL-1, which sensitizes malignant cells to venetoclax. This triple-drug combination is being evaluated in Phase 2 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
- Brand names
- TevimbraVidazaOnureg
- Other names
- PD-1 Inhibitor + venetoclax + decitabine + azacytidineTislelizumab + Venetoclax + HMAVA + PD-1 inhibitorTislelizumab + Venetoclax + DecitabineTislelizumab + Venetoclax + Azacitidine
02
Targets
DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT3A (DNA methyltransferase 3 alpha)Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)PDCD1 (Programmed cell death protein 1 receptor)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on tislelizumab + venetoclax + decitabine + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + venetoclax + decitabine + azacitidine.